Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [4]. - The company’s public statements regarding its business and financial prospects were claimed to be materially false and misleading [4]. Group 3: Stock Price Impact - Following a press release on July 7, 2025, which revealed issues with a drug product lot and subsequent halting of studies, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share [5]. Group 4: Company Actions - Jasper announced it would implement cost-cutting measures, including potential restructuring, to extend its financial runway and reduce expenses, contradicting previous claims of a strong balance sheet [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc due to allegations of misleading investors about the strength of its North America Fiber Cement segment, leading to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $100,000 in James Hardie between May 20, 2025, and August 18, 2025, to contact them for legal options [1]. - A federal securities class action has been filed against James Hardie, with a deadline of December 23, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against James Hardie - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements and failing to disclose that the company misled investors regarding the strength of its North America Fiber Cement segment during the specified period [6]. - Despite knowing about inventory destocking by distributors, James Hardie falsely claimed that demand remained strong and that stock levels were "normal" [6]. Group 3: Financial Impact - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected fiscal 2026 earnings due to high borrowing costs [6]. - Following the announcement, James Hardie's American Depositary Receipt (ADR) price fell by $9.79, or 34.44%, closing at $18.64 per ADR on August 20, 2025 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the October 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - Investors who suffered losses in Unicycive between March 29, 2024, and June 27, 2025, are encouraged to contact the firm to discuss their legal rights [1][4]. Group 2: Allegations Against Unicycive - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. - On June 10, 2025, Unicycive disclosed deficiencies in cGMP compliance at a third-party manufacturing vendor, leading to a stock price drop of $3.68 per share, or 40.89%, closing at $5.32 [7]. - Following a Complete Response Letter from the FDA on June 30, 2025, citing the same cGMP deficiencies, Unicycive's stock fell by $2.03 per share, or 29.85%, closing at $4.77 [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against SelectQuote, Inc. due to allegations of misleading practices related to Medicare insurance plans, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by October 10, 2025 [4][6]. Group 1: Allegations Against SelectQuote - The complaint alleges that SelectQuote directed Medicare beneficiaries to plans that compensated the company best, regardless of quality [6]. - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage plans and received illegal kickbacks from insurers [6]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in stock price [7]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased SelectQuote securities between September 9, 2020, and May 1, 2025, are encouraged to discuss their legal rights and options [1][4]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the deadline for applications set for October 10, 2025 [8]. - Faruqi & Faruqi is also seeking information from whistleblowers and former employees regarding SelectQuote's conduct [9].